Beranda › Karsinoma Sel Renal Metastatik Sel Jernih › Florida
Uji klinis Karsinoma Sel Renal Metastatik Sel Jernih di Florida
5 studi untuk Karsinoma Sel Renal Metastatik Sel Jernih mencari peserta di lokasi di Florida.
Kota di Florida
Teks studi resmi (Bahasa Inggris)
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
- NEO-811 Florida Site, Miami
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT07300241Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
- Research Site, Jacksonville
- Research Site, Miami
- Research Site, Orlando
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07011719Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Mayo Clinic Pharmacy, Jacksonville
- Orlando Health Ambulatory Care Center, Orlando
- Orlando Health Cancer Institute, Orlando
- dan 1 lainnya
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07227415Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
- Mayo Clinic in Florida, Jacksonville
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Mar 2026 · NCT06349642Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- AdventHealth Altamonte, Altamonte Springs
- AdventHealth Celebration, Celebration
- AdventHealth Kissimmee, Kissimmee
- dan 5 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2025 · NCT04510597Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.